This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features!

Skip to main page content

Add to Collections

Your saved search

Name of saved search:

Search terms:

Test search terms

Would you like email updates of new search results?

Yes
No

Email: (change)

Frequency:

Which day?

Which day?

Report format:

Send at most:

Send even when there aren't any new results

Optional text in email:

Your RSS Feed

Comment

. 2021 Mar 1;4(3):e211061.

doi: 10.1001/jamanetworkopen.2021.1061.

Cancer and Neurofibromatosis Type 1-Confirming What We Knew and Telling Us Something New

Thierry Alcindor¹

Affiliations

PMID: 33734408
DOI: 10.1001/jamanetworkopen.2021.1061

Free article

Comment

Cancer and Neurofibromatosis Type 1-Confirming What We Knew and Telling Us Something New

Thierry Alcindor. JAMA Netw Open. 2021.

Free article

. 2021 Mar 1;4(3):e211061.

doi: 10.1001/jamanetworkopen.2021.1061.

Author

Thierry Alcindor¹

Affiliation

¹ Gerald Bronfman Department of Oncology, McGill University, Cedars Cancer Center, McGill University Health Centre, Montreal, Quebec, Canada.

PMID: 33734408
DOI: 10.1001/jamanetworkopen.2021.1061

No abstract available

PubMed Disclaimer

Comment on

Comparison of Cancer Prevalence in Patients With Neurofibromatosis Type 1 at an Academic Cancer Center vs in the General Population From 1985 to 2020.
Landry JP, Schertz KL, Chiang YJ, Bhalla AD, Yi M, Keung EZ, Scally CP, Feig BW, Hunt KK, Roland CL, Guadagnolo A, Bishop AJ, Lazar AJ, Slopis JM, McCutcheon IE, Torres KE. Landry JP, et al. JAMA Netw Open. 2021 Mar 1;4(3):e210945. doi: 10.1001/jamanetworkopen.2021.0945. JAMA Netw Open. 2021. PMID: 33734413 Free PMC article.

Publication types

Actions

MeSH terms

Actions
Actions
Actions
Actions

LinkOut - more resources

Full Text Sources
- Ovid Technologies, Inc.
- Silverchair Information Systems
Other Literature Sources
- scite Smart Citations
Research Materials
- NCI CPTC Antibody Characterization Program